VERRICA PHARMACEUTICALS INC (VRCA) Fundamental Analysis & Valuation

NASDAQ:VRCA • US92511W2070

Current stock price

5.47 USD
-0.02 (-0.36%)
At close:
5.47 USD
0 (0%)
After Hours:

This VRCA fundamental analysis includes valuation metrics, fair value assessment, financial health analysis, profitability trends, growth metrics and dividend sustainability analysis.

2

1. VRCA Profitability Analysis

1.1 Basic Checks

  • VRCA had negative earnings in the past year.
  • VRCA had a negative operating cash flow in the past year.
  • In the past 5 years VRCA always reported negative net income.
  • VRCA had a negative operating cash flow in each of the past 5 years.
VRCA Yearly Net Income VS EBIT VS OCF VS FCFVRCA Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 -20M -40M -60M

1.2 Ratios

  • VRCA has a Return On Assets of -37.95%. This is comparable to the rest of the industry: VRCA outperforms 43.75% of its industry peers.
  • VRCA has a Return On Equity (-72.29%) which is comparable to the rest of the industry.
Industry RankSector Rank
ROA -37.95%
ROE -72.29%
ROIC N/A
ROA(3y)-87.17%
ROA(5y)-72.01%
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
VRCA Yearly ROA, ROE, ROICVRCA Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 0 500 -500 -1K

1.3 Margins

  • VRCA has a better Gross Margin (90.33%) than 92.19% of its industry peers.
  • VRCA's Gross Margin has been stable in the last couple of years.
  • The Profit Margin and Operating Margin are not available for VRCA so they could not be analyzed.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM 90.33%
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-0.62%
GM growth 5YN/A
VRCA Yearly Profit, Operating, Gross MarginsVRCA Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 0 -200 -400 -600 -800 -1K

More info and screens

ROAROEROICOperating and Profit MarginShow most profitable peers

3

2. VRCA Health Analysis

2.1 Basic Checks

  • VRCA does not have a ROIC to compare to the WACC, probably because it is not profitable.
  • VRCA has more shares outstanding than it did 1 year ago.
  • Compared to 5 years ago, VRCA has more shares outstanding
  • VRCA has a better debt/assets ratio than last year.
VRCA Yearly Shares OutstandingVRCA Yearly Shares OutstandingYearly Shares Outstanding 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 5M 10M 15M
VRCA Yearly Total Debt VS Total AssetsVRCA Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 20M 40M 60M 80M

2.2 Solvency

  • VRCA has an Altman-Z score of -6.55. This is a bad value and indicates that VRCA is not financially healthy and even has some risk of bankruptcy.
  • VRCA has a Altman-Z score of -6.55. This is in the lower half of the industry: VRCA underperforms 67.71% of its industry peers.
  • VRCA has a Debt/Equity ratio of 0.03. This is a healthy value indicating a solid balance between debt and equity.
  • Looking at the Debt to Equity ratio, with a value of 0.03, VRCA is in line with its industry, outperforming 55.21% of the companies in the same industry.
Industry RankSector Rank
Debt/Equity 0.03
Debt/FCF N/A
Altman-Z -6.55
ROIC/WACCN/A
WACC11.82%
VRCA Yearly LT Debt VS Equity VS FCFVRCA Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 0 50M -50M

2.3 Liquidity

  • VRCA has a Current Ratio of 2.59. This indicates that VRCA is financially healthy and has no problem in meeting its short term obligations.
  • The Current ratio of VRCA (2.59) is comparable to the rest of the industry.
  • VRCA has a Quick Ratio of 2.45. This indicates that VRCA is financially healthy and has no problem in meeting its short term obligations.
  • VRCA has a Quick ratio (2.45) which is comparable to the rest of the industry.
Industry RankSector Rank
Current Ratio 2.59
Quick Ratio 2.45
VRCA Yearly Current Assets VS Current LiabilitesVRCA Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 20M 40M 60M 80M

More info and screens

WACCDebt/EquityHow to determine the health of a companyAltman-Z scoreShow peers with great health

7

3. VRCA Growth Analysis

3.1 Past

  • The Earnings Per Share has grown by an impressive 90.45% over the past year.
  • The Revenue has grown by 370.22% in the past year. This is a very strong growth!
  • The Revenue has been growing by 57.94% on average over the past years. This is a very strong growth!
EPS 1Y (TTM)90.45%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%80.83%
Revenue 1Y (TTM)370.22%
Revenue growth 3Y57.94%
Revenue growth 5YN/A
Sales Q2Q%1380.23%

3.2 Future

  • The Earnings Per Share is expected to grow by 35.50% on average over the next years. This is a very strong growth
  • Based on estimates for the next years, VRCA will show a very strong growth in Revenue. The Revenue will grow by 40.85% on average per year.
EPS Next Y17.96%
EPS Next 2Y36.68%
EPS Next 3Y84.03%
EPS Next 5Y35.5%
Revenue Next Year-28.36%
Revenue Next 2Y17.31%
Revenue Next 3Y35.48%
Revenue Next 5Y40.85%

3.3 Evolution

  • The estimated forward Revenue growth is still strong, although it is decreasing when compared to the stronger growth in the past years.
VRCA Yearly Revenue VS EstimatesVRCA Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 2032 2033 50M 100M 150M 200M 250M
VRCA Yearly EPS VS EstimatesVRCA Yearly EPS VS EstimatesYearly EPS VS Estimates 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 2032 2033 0 5 -5 -10 -15

More info and screens

Find the best growth stocksShow best growing peers

1

4. VRCA Valuation Analysis

4.1 Price/Earnings Ratio

  • VRCA reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
  • Also next year VRCA is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.
Industry RankSector Rank
PE N/A
Fwd PE N/A
VRCA Price Earnings VS Forward Price EarningsVRCA Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 40

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
VRCA Per share dataVRCA EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 1 -1 2

4.3 Compensation for Growth

  • VRCA's earnings are expected to grow with 84.03% in the coming years. This may justify a more expensive valuation.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y36.68%
EPS Next 3Y84.03%

More info and screens

Price/EarningsPrice/FCFFCF per shareEV/EBITDAPEG RATIOShow best valued peers

0

5. VRCA Dividend Analysis

5.1 Amount

  • VRCA does not give a dividend.
Industry RankSector Rank
Dividend Yield 0%

More info and screens

Find the best dividend stocksShow peers with best dividend

VRCA Fundamentals: All Metrics, Ratios and Statistics

VERRICA PHARMACEUTICALS INC

NASDAQ:VRCA (4/2/2026, 8:00:40 PM)

After market: 5.47 0 (0%)

5.47

-0.02 (-0.36%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryPharmaceuticals
Earnings (Last)03-11
Earnings (Next)05-11
Inst Owners32.57%
Inst Owner Change0%
Ins Owners30.12%
Ins Owner Change11.79%
Market Cap93.97M
Revenue(TTM)35.58M
Net Income(TTM)-17.89M
Analysts81.82
Price Target16.83 (207.68%)
Short Float %5.46%
Short Ratio3.4
Dividend
Industry RankSector Rank
Dividend Yield 0%
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)69.43%
Min EPS beat(2)43.23%
Max EPS beat(2)95.64%
EPS beat(4)3
Avg EPS beat(4)60.27%
Min EPS beat(4)-0.55%
Max EPS beat(4)102.78%
EPS beat(8)5
Avg EPS beat(8)28.3%
EPS beat(12)7
Avg EPS beat(12)16.01%
EPS beat(16)10
Avg EPS beat(16)23.08%
Revenue beat(2)2
Avg Revenue beat(2)75.51%
Min Revenue beat(2)10.31%
Max Revenue beat(2)140.71%
Revenue beat(4)4
Avg Revenue beat(4)94.11%
Min Revenue beat(4)10.31%
Max Revenue beat(4)191.87%
Revenue beat(8)6
Avg Revenue beat(8)27.8%
Revenue beat(12)9
Avg Revenue beat(12)71.01%
Revenue beat(16)11
Avg Revenue beat(16)55.88%
PT rev (1m)0%
PT rev (3m)0%
EPS NQ rev (1m)6.73%
EPS NQ rev (3m)6.73%
EPS NY rev (1m)0%
EPS NY rev (3m)0%
Revenue NQ rev (1m)-17.86%
Revenue NQ rev (3m)-24.59%
Revenue NY rev (1m)-10.63%
Revenue NY rev (3m)-5.29%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 2.64
P/FCF N/A
P/OCF N/A
P/B 3.8
P/tB 3.8
EV/EBITDA N/A
EPS(TTM)-1.47
EYN/A
EPS(NY)-1.21
Fwd EYN/A
FCF(TTM)-1.03
FCFYN/A
OCF(TTM)-1.03
OCFYN/A
SpS2.07
BVpS1.44
TBVpS1.44
PEG (NY)N/A
PEG (5Y)N/A
Graham NumberN/A
Profitability
Industry RankSector Rank
ROA -37.95%
ROE -72.29%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM 90.33%
FCFM N/A
ROA(3y)-87.17%
ROA(5y)-72.01%
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-0.62%
GM growth 5YN/A
F-Score6
Asset Turnover0.75
Health
Industry RankSector Rank
Debt/Equity 0.03
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 0%
Cap/Sales 0%
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 2.59
Quick Ratio 2.45
Altman-Z -6.55
F-Score6
WACC11.82%
ROIC/WACCN/A
Cap/Depr(3y)22.88%
Cap/Depr(5y)100.39%
Cap/Sales(3y)2.47%
Cap/Sales(5y)3.62%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)90.45%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%80.83%
EPS Next Y17.96%
EPS Next 2Y36.68%
EPS Next 3Y84.03%
EPS Next 5Y35.5%
Revenue 1Y (TTM)370.22%
Revenue growth 3Y57.94%
Revenue growth 5YN/A
Sales Q2Q%1380.23%
Revenue Next Year-28.36%
Revenue Next 2Y17.31%
Revenue Next 3Y35.48%
Revenue Next 5Y40.85%
EBIT growth 1Y81.89%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year-138.48%
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y71.08%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y71.07%
OCF growth 3YN/A
OCF growth 5YN/A

VERRICA PHARMACEUTICALS INC / VRCA Fundamental Analysis FAQ

What is the ChartMill fundamental rating of VERRICA PHARMACEUTICALS INC (VRCA) stock?

ChartMill assigns a fundamental rating of 3 / 10 to VRCA.


What is the valuation status of VERRICA PHARMACEUTICALS INC (VRCA) stock?

ChartMill assigns a valuation rating of 1 / 10 to VERRICA PHARMACEUTICALS INC (VRCA). This can be considered as Overvalued.


What is the profitability of VRCA stock?

VERRICA PHARMACEUTICALS INC (VRCA) has a profitability rating of 2 / 10.


Can you provide the financial health for VRCA stock?

The financial health rating of VERRICA PHARMACEUTICALS INC (VRCA) is 3 / 10.


Can you provide the expected EPS growth for VRCA stock?

The Earnings per Share (EPS) of VERRICA PHARMACEUTICALS INC (VRCA) is expected to grow by 17.96% in the next year.